Cava's first-quarter revenue increased 30.3% year-over-year to $256.3 million, which beat the consensus estimate of $245.935 million, according to Benzinga Pro.
Quarterly supplemental dividends of $0.075 per share represent a 20% increase in dividend payments to common shareholders Increased dividend payments reflect material outperformance of containership charter
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer